The Injective Protocol has recently made a significant comeback, capturing attention with substantial capital inflows. Over the past month, it recorded a net inflow of approximately $142 million, ranking second only to Ethereum among all major blockchain networks. This influx is accompanied by notable increases in on-chain fees, active users, and token trading volume. But what does this mean for this established layer-1 blockchain? Is this surge a sign of sustainable growth or merely a temporary spike?
Understanding the $142 Million Capital Inflow
Data up to June 4 reveals that Injective attracted $142 million in net inflows. While the absolute value may not be the highest, its ranking is impressive. A deeper analysis shows that this net figure stems not from exceptionally high inflows alone but from minimal outflows—only $11 million during the same period. In terms of gross inflow, Injective ranked around tenth, but its near-zero outflows propelled it to the second spot in net flow rankings.
A remarkable 98.5% of these inflows, about $140 million, occurred via the Peggy cross-chain bridge. According to a May 26 report by market analysis firm Keyrock titled "Key Insights, Bond Appetit," this movement was primarily driven by the launch of Upshift, an institutional-grade yield platform, on the Injective network. Upshift offered a treasury APY of 30%, which likely acted as a magnet for capital migration.
However, it's worth noting that Upshift's treasury on Injective had a hard cap of $5 million. This limited capacity suggests that a significant portion of the incoming funds may not have been absorbed and could exit shortly, posing a risk of short-term volatility.
👉 Explore more strategies for evaluating yield platforms
Strategic Pivot: From Derivatives to RWA Focus
Beyond capital movements, Injective has undergone substantial ecological shifts. The April 22 launch of the Lyora mainnet upgrade marked a key milestone, introducing technical enhancements like a dynamic fee structure and a smart mempool. These improvements aim to boost transaction speed, reduce latency, and increase throughput.
Injective has also rolled out iAssets, a dedicated oracle framework for real-world assets (RWA). Upshift's treasury is itself an RWA DeFi vault. On May 29, Injective announced the launch of on-chain forex markets for EUR and GBP using the iAsset framework, signaling a strategic pivot towards RWA integration.
Originally, Injective's core narrative centered on decentralized derivatives trading. It evolved from a derivatives exchange into a full-fledged blockchain, similar to the path taken by Hyperliquid. Yet, Injective's derivatives performance has lagged. As of June 4, its highest-volume BTC perpetual contract pair saw $39.75 million in trades, with total derivatives volume around $90 million. In contrast, Hyperliquid recorded about $7 billion—77 times higher.
This underperformance may explain Injective's shift towards RWA. The new direction shows some promise: on May 22, derivatives volume peaked at $1.97 billion, significantly above typical levels, and has generally trended upward recently.
Daily active users have also surged, from a low of 6,300 addresses in February to 47,900 recently—a 7.6x increase. Although this ranks only 12th among blockchains, the rapid growth surpasses networks like Avalanche and Berachain.
Despite these gains, Injective's total value locked (TVL) has not followed suit. Since March 2024, TVL has declined steadily, currently standing at $26.33 million. This indicates that DeFi projects on Injective still struggle to attract and retain capital.
INJ Token Performance: Short-Term Rally vs. Long-Term Challenges
INJ, the native governance token, has a market cap of about $1.26 billion, ranking 82nd globally. It remains 76% below its all-time high市值 of $5.3 billion. However, from its April low of $6.34, it rallied to $15.48—a 144% gain that stands out among established blockchains. Whether this momentum can sustain is uncertain.
Injective has also secured partnerships with notable entities like Republic, Google Cloud, and Deutsche Telekom MMS, which have joined as validators. Additionally, it has introduced AI-related products, aligning with emerging narratives like AI and RWA.
Overall, Injective is actively transforming itself by embracing new trends. Data through June shows measurable growth, though it still trails leading blockchains by a wide margin. This challenge is not unique to Injective; many once-prominent blockchains from the last cycle face similar struggles, often rebranding or upgrading in attempts to regain relevance.
The current revival efforts are still in early stages. The Upshift-driven inflows serve as a test of market sentiment and ecological potential rather than a definitive turnaround. The success of its RWA strategy in creating competitive advantages and fostering sustained growth will depend on overcoming existing hurdles and passing long-term market tests.
Frequently Asked Questions
What caused the recent capital inflow into Injective?
The inflow was primarily driven by Upshift, a yield platform offering 30% APY on treasuries. Most funds entered via the Peggy bridge, though the treasury's $5 million cap limited absorption.
How does Injective's derivatives trading compare to competitors?
Injective's derivatives volume is significantly lower than rivals like Hyperliquid. On June 4, its total was $90 million versus Hyperliquid's $7 billion, highlighting a substantial gap.
What is Injective's new strategic focus?
Injective is pivoting towards real-world assets (RWA) with tools like the iAssets oracle framework and on-chain forex markets, moving away from its original derivatives-centric model.
Has user activity on Injective increased?
Daily active addresses grew 7.6x from February to 47,900, indicating rising interest, though TVL has not followed, suggesting capital retention remains a challenge.
What is the outlook for the INJ token?
INJ rallied 144% from April lows but remains far below its peak. Partnerships and AI integrations offer potential, but sustained growth depends on broader adoption and ecological development.
Is Injective's growth sustainable?
While recent data is positive, Injective faces stiff competition and must prove its RWA and AI strategies can deliver long-term value beyond short-term spikes.